TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9640152
Drug: remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1 with glycopyrrolate 200 micrograms
Study: 9640152
Drug: glycopyrrolate 200
Normalized name: Glycopyrrolate 200 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate 200 micrograms and remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Study: 2645918
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 to 120 mg/d given in divided dosage) for twelve weeks
Study: 2645918
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 to 120 mg/d given in divided dosage) for four weeks
Study: 31688091
Drug: Antisense-oligonucleotide therapy
Normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisense-oligonucleotide therapy
Study: 31688091
Drug: RNA interference
Normalized name: Double stranded oligomer ADS-001 RNA interference-based liver targeted therapeutic
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA interference therapy
Study: 18512816
Drug: Oral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bovine type I collagen (500 microg/day)
Study: 15070917
Drug: Flutamide (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (62.5 mg/d) plus Metformin (850 mg/d)
Study: 15070917
Drug: Ethinylestradiol-drospirenone (OC)
Normalized name: drospirenone and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol-drospirenone (OC) plus Flutamide-Metformin
Study: 1679659
Drug: Clobazam 10
Normalized name: cloBAZam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 10 mg
Study: 26087226
Drug: Web-based alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based alcohol treatment program with intensive asynchronous therapeutic support
Study: 15283001
Drug: L-dopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (200 mg) plus carbidopa (50 mg) administered at night (11 pm)
Study: 15283001
Drug: L-dopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (200 mg) plus carbidopa (50 mg) administered during the day (11 am)
Study: 8989345
Drug: 750 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/kg RSV‐IGIV
Study: 8235924
Drug: Cefotaxime 500
Normalized name: cefotaxime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 500 mg intramuscularly
Study: 3321412
Drug: Norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 200 mg or 400 mg b.i.d. for 7 days
Study: 11918228
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of cod liver oil with vitamin D (n = 575)
Study: 11918228
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of cod liver oil without vitamin D (n = 569)
Study: 26242794
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of depression
Study: 9439181
Drug: Obesity/diabetes mellitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obesity/diabetes mellitus treatment
Study: 8129410
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin (0.025% cream)
Study: 8129410
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral isotretinoin (10 mg/d)
Study: 148436
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream
Study: 2679513
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal gel (1 or 2mg, repeated if necessary at 6 hours)
Study: 21123762
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of atrial natriuretic peptide (ANP) at 10 ng·kg(‐1)·min(‐1)
Study: 21123762
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of angiotensin II (ANG II) at 10 ng·kg(‐1)·min(‐1)
Study: 21123762
Drug: ANG II
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANG II with simultaneous infusion of nitroprusside
Study: 21123762
Drug: Simultaneous intravenous
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous intravenous infusion of ANP (10 ng·kg(‐1)·min(‐1)) with ANG II and nitroprusside
Study: 19204058
Drug: Postnatal corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal corticosteroids (dexamethasone), total dose tertiles: <0.9, 0.9‐1.9, and >/=1.9 mg/kg
Study: 15365275
Drug: Lisinopril up-titration
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril up-titration (40 mg for 8 weeks)
Study: 15365275
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus candesartan (16 mg for 2 weeks followed by 32 mg for 6 weeks)
Study: 15365275
Drug: Post hoc
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post hoc pooled analysis of lisinopril plus candesartan
Study: 10321674
Drug: Pentoxifylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (5 mg/kg/hr for 6 hrs on 6 successive days)
Study: 2018406
Drug: Short recall
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short recall periods (e.g., last weekend, the past 5 days) (Study 3)
Study: 26679977
Drug: Nasally inhaled
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasally inhaled isopropyl alcohol
Study: 26679977
Drug: Nasally inhaled
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasally inhaled normal saline solution (placebo)
Study: 24845609
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg, 3 times daily)
Study: 28043903
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg daily)
Study: 22194371
Drug: Posterior vertebral
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior vertebral arch cement augmentation (spinoplasty)
Study: 19063731
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin therapy (10 ml/kg over 4-6 hours, repeated 48 hours later)
Study: 11818199
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT 300 mg/m2/day plus oral LV 90 mg/day for 28 days every 5 weeks
Study: 11818199
Drug: i.v. 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 5‐FU 425 mg/m2/day plus LV 20 mg/m2/day for 5 days every 4 weeks
Study: 15842464
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT
Study: 8820252
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg capsules)
Study: 19362675
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg intravenous infusion)
Study: 25510286
Drug: Oral fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fish oil supplementation
Study: 23623849
Drug: Phenytoin/Valproate (third-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin/Valproate (third-line standard treatment)
Study: 21823043
Drug: Pioglitazone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-30 mg/day)
Study: 21823043
Drug: Metformin (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500-750 mg/day)
Study: 15720808
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-FU
Study: 11401110
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (EPO) and intravenous (IV) iron
Study: 9424006
Drug: Hyperfractionated XRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated XRT (total dose 69.60‐76.80 Gy, 1.2 Gy b.i.d. five times a week) combined with superficial external HT (2 to 6 sessions)
Study: 24921211
Drug: Rabeprazole, Amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole, Amoxicillin, and Metronidazole (RAM)
Study: 22091740
Drug: Short-acting β‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β‐agonist
Study: 19071883
Drug: Mipomersen sodium
Normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mipomersen sodium 200 mg
Study: 12893645
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose house dust mite allergen exposure
Study: 8268899
Drug: Combined tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined tablet containing hydrochlorothiazide 25 mg and amiloride 2.5 mg
Study: 29400921
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg once daily for up to 28 days
Study: 28251654
Drug: BGCC (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGCC (3 g d-1) for 12 weeks
Study: 19738017
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of n-propanol with CHG
Study: 16368077
Drug: Dexamethasone/corticotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone/corticotropin-releasing hormone (DEX/CRH) test after 8 weeks of antidepressant treatment
Study: 6140261
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg and 10 mg)
Study: 7996118
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (KT) 60 mg to 2 ml
Study: 31778291
Drug: Stratified exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified exercise therapy (subgroup-specific protocolized exercise therapy, with dietary intervention for obesity subgroup)
Study: 31778291
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care by physical therapists (nonstratified exercise therapy)
Study: 28502744
Drug: High-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sodium selenite (4000 μg IV after induction, 1000 μg/d during ICU stay)
Study: 25142039
Drug: Memantine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5 to 20 mg/day; n=20)
Study: 10757577
Drug: Prilocaine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (80 mg, 20 mg/ml)
Study: 10757577
Drug: Lidocaine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (80 mg, 20 mg/ml)
Study: 1591947
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg orally 4 times a day)
Study: 1591947
Drug: Dimethyl sulphoxide
Normalized name: Dimethyl sulphoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dimethyl sulphoxide (DMSO, 500 mg orally 4 times a day)
Study: 14512398
Drug: Tailored fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy for nine courses
Study: 14512398
Drug: Induction FEC
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction FEC therapy for three courses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb)
Study: 14512398
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FEC and CTCb)
Study: 11249802
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 to 3,600 mg/day)
Study: 1888819
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine suspension four times daily
Study: 28578208
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioural Therapy (ICBT)
Study: 19931380
Drug: Inactivated, subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, subvirion vaccine containing 15microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route
Study: 19931380
Drug: Inactivated, subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, subvirion vaccine containing 45microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route
Study: 19931380
Drug: Inactivated, subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, subvirion vaccine containing 3microg of H5 HA by the intradermal (ID) route
Study: 19931380
Drug: Inactivated, subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, subvirion vaccine containing 9microg of H5 HA by the intradermal (ID) route
Study: 19931380
Drug: Inactivated, subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, subvirion vaccine containing 45microg of H5 HA by the intramuscular (IM) route
Study: 19931380
Drug: Inactivated, subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, subvirion vaccine containing 15microg of H5 HA by the intramuscular (IM) route
Study: 22863058
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g colestyramine
Study: 22863058
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g colestyramine
Study: 22863058
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of colestyramine
Study: 12615670
Drug: rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (8 mg)
Study: 2483004
Drug: Neoadjuvant PVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant PVB therapy
Study: 2483004
Drug: Neoadjuvant CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant CAP therapy
Study: 55648
Drug: Levamisole (1-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (1-25 mg/kg twice daily for two consecutive days every week)
Study: 55648
Drug: Levamisole (greater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (greater than 2-5 mg/kg/day)
Study: 30983001
Drug: 0.1% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% triamcinolone acetonide cream with wet wraps
Study: 30983001
Drug: 0.1% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% triamcinolone acetonide ointment with wet wraps
Study: 30983001
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for ointment
Study: 23350579
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (10 mL of Evicel)
Study: 21722228
Drug: Acetaminophen (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500-1000 mg) + Ibuprofen (100-400 mg)
Study: 21722228
Drug: Ibuprofen (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (100-400 mg)
Study: 21722228
Drug: Acetaminophen (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500-1000 mg)
Study: 10620007
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements and dietary counselling
Study: 10620007
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no supplements or specific nutritional advice)
Study: 1585291
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day for 10 days
Study: 1585291
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg six hourly for 10 days
Study: 4032549
Drug: 3 gm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 gm. ampicillin intramuscularly in divided doses 1 hour before, at the time of, and 6 hours after catheter insertion (Group 1)
Study: 21956438
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered 6% v/v ethanol to a target blood alcohol concentration of 0.08%
Study: 21956438
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered 6% v/v ethanol
Study: 12322847
Drug: Loratadine plus
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine plus Pseudoephedrine Sulfate Repetabs Tables (LTD+PSE Repetabs) (Loratadine 5 mg + Pseudoephedrine 120 mg) twice daily
Study: 12322847
Drug: loratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine (5 mg) twice daily and pseudoephedrine (60 mg) quarter daily
Study: 9925128
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL black currant and apple juice
Study: 9925128
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL black currant and apple juice
Study: 9925128
Drug: 1500 mL
Normalized name: Bag/Pump Set 1500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mL black currant and apple juice
Study: 7589375
Drug: Terbutaline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline and budesonide turbohalers used twice daily over 12 weeks
Study: 2156387
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated rotavirus vaccine (derived from rhesus rotavirus strain MMU 18006 and human serotype 1 strain Wa)
Study: 2156387
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated rotavirus vaccine
Study: 28395659
Drug: Abelmoschus manihot
Normalized name: ABELMOSCHUS MANIHOT WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelmoschus manihot (huangkui capsule, 2.5 g, three times per day)
Study: 28395659
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (100 mg/d)
Study: 26802783
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) + deferred laser (N = 111)
Study: 26802783
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) + prompt laser (N = 124)
Study: 26802783
Drug: Triamcinolone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (4 mg) + laser/very deferred ranibizumab (N = 125)
Study: 22249272
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (G)
Study: 18187961
Drug: E-CMF (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-CMF (adjuvant anthracycline-based dose-dense sequential chemotherapy)
Study: 18187961
Drug: E-T-CMF (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-T-CMF (adjuvant anthracycline-based dose-dense sequential chemotherapy)
Study: 12390062
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (≤325 mg/d)
Study: 22623392
Drug: MUFA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUFA diet (20% daily energy MUFA)
Study: 22623392
Drug: MED diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED diet (21% daily energy MUFA)
Study: 22623392
Drug: SFA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFA diet (19% daily energy as SFA)
Study: 19198574
Drug: Daily interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interferon alpha‐2b (4 MIU s.c. for patients > 65 kg or 0.06 MIU/kg < 65 kg) + ribavirin
Study: 19198574
Drug: PEG‐interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐interferon alpha‐2b (100 microg s.c. weekly for patients > 65 kg or 1.5 microg/kg weekly for patients < 65 kg) + ribavirin
Study: 16370079
Drug: Olanzapine (Zyprexa)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (Zyprexa) 7.5 mg
Study: 16370079
Drug: Quetiapine (Seroquel)
Normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine (Seroquel) 200 mg
Study: 16370079
Drug: Risperidone (Risperdal)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone (Risperdal) 1.5 mg
Study: 16370079
Drug: Ziprasidone (Geodon)
Normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone (Geodon) 40 mg
Study: 16370079
Drug: Perphenazine (Trilafon)
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perphenazine (Trilafon) 8 mg
Study: 15156097
Drug: Chlorpheniramine high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine high dose (12 mg)
Study: 15156097
Drug: Chlorpheniramine low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine low dose (4 mg)
Study: 15156097
Drug: Chlorpheniramine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (both doses)
Study: 8337193
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment programme in a group setting with components of relaxation, cognitive restructuring, and promotion of well-being
Study: 8337193
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment programme
Study: 3709586
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine injection (group A)
Study: 3709586
Drug: No epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epidural morphine (group B)
Study: 3169499
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (starting dosage, 2.5 mg/kg.day)